696 related articles for article (PubMed ID: 25760296)
1. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
Astorri E; Nerviani A; Bombardieri M; Pitzalis C
Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
Gibbons LJ; Hyrich KL
BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Rheumatoid Arthritis, what is new?
Gavrilă BI; Ciofu C; Stoica V
J Med Life; 2016; 9(2):144-8. PubMed ID: 27453744
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F; Durez P; Buch MH; Lewis MJ; Rizvi H; Rivellese F; Nerviani A; Giorli G; Mahto A; Montecucco C; Lauwerys B; Ng N; Ho P; Bombardieri M; Romão VC; Verschueren P; Kelly S; Sainaghi PP; Gendi N; Dasgupta B; Cauli A; Reynolds P; Cañete JD; Moots R; Taylor PC; Edwards CJ; Isaacs J; Sasieni P; Choy E; Pitzalis C;
Lancet; 2021 Jan; 397(10271):305-317. PubMed ID: 33485455
[TBL] [Abstract][Full Text] [Related]
5. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
Rivellese F; Nerviani A; Giorli G; Warren L; Jaworska E; Bombardieri M; Lewis MJ; Humby F; Pratt AG; Filer A; Gendi N; Cauli A; Choy E; McInnes I; Durez P; Edwards CJ; Buch MH; Gremese E; Taylor PC; Ng N; Cañete JD; Raizada S; McKay ND; Jadon D; Sainaghi PP; Stratton R; Ehrenstein MR; Ho P; Pereira JP; Dasgupta B; Gorman C; Galloway J; Chinoy H; van der Heijde D; Sasieni P; Barton A; Pitzalis C;
Lancet Rheumatol; 2023 Nov; 5(11):e648-e659. PubMed ID: 38251532
[TBL] [Abstract][Full Text] [Related]
6. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
Dennis G; Holweg CT; Kummerfeld SK; Choy DF; Setiadi AF; Hackney JA; Haverty PM; Gilbert H; Lin WY; Diehl L; Fischer S; Song A; Musselman D; Klearman M; Gabay C; Kavanaugh A; Endres J; Fox DA; Martin F; Townsend MJ
Arthritis Res Ther; 2014; 16(2):R90. PubMed ID: 25167216
[TBL] [Abstract][Full Text] [Related]
7. Bilateral evaluation of the hand and wrist in untreated early inflammatory arthritis: a comparative study of ultrasonography and magnetic resonance imaging.
Navalho M; Resende C; Rodrigues AM; Pereira da Silva JA; Fonseca JE; Campos J; Canhão H
J Rheumatol; 2013 Aug; 40(8):1282-92. PubMed ID: 23729806
[TBL] [Abstract][Full Text] [Related]
8. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
Agarwal SK
J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
[TBL] [Abstract][Full Text] [Related]
9. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis.
Orr C; Najm A; Biniecka M; McGarry T; Ng CT; Young F; Fearon U; Veale DJ
Arthritis Rheumatol; 2017 Nov; 69(11):2114-2123. PubMed ID: 28732135
[TBL] [Abstract][Full Text] [Related]
10. Are rheumatoid arthritis patients discernible from other early arthritis patients using 1.5T extremity magnetic resonance imaging? a large cross-sectional study.
Stomp W; Krabben A; van der Heijde D; Huizinga TW; Bloem JL; van der Helm-van Mil AH; Reijnierse M
J Rheumatol; 2014 Aug; 41(8):1630-7. PubMed ID: 25028382
[TBL] [Abstract][Full Text] [Related]
11. Th17 and CD24
Salomon S; Guignant C; Morel P; Flahaut G; Brault C; Gourguechon C; Fardellone P; Marolleau JP; Gubler B; Goëb V
Arthritis Res Ther; 2017 Feb; 19(1):33. PubMed ID: 28183330
[TBL] [Abstract][Full Text] [Related]
12. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid arthritis: Biological therapy other than anti-TNF.
Rossi D; Modena V; Sciascia S; Roccatello D
Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
[TBL] [Abstract][Full Text] [Related]
14. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
D'Agostino MA; Wakefield RJ; Berner-Hammer H; Vittecoq O; Filippou G; Balint P; Möller I; Iagnocco A; Naredo E; Østergaard M; Boers M; Gaillez C; Van Holder K; Le Bars M;
Ann Rheum Dis; 2016 Oct; 75(10):1763-9. PubMed ID: 26590174
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
[TBL] [Abstract][Full Text] [Related]
16. High-grade synovitis associates with clinical markers and response to therapy in chronic inflammatory arthritis:
Garaffoni C; Tamussin M; Calciolari I; Lanza G; Bortoluzzi A; Scirè CA; Govoni M; Silvagni E
Front Immunol; 2023; 14():1298583. PubMed ID: 38274811
[TBL] [Abstract][Full Text] [Related]
17. Cytokinin panel in rheumatoid arthritis and correlation with histological patterns of synovitis -- active type of disease.
Avrămescu C; Vere CC; Mărgăritescu C; Turculeanu A; Bălăşoiu M; Rogoz S
Rom J Morphol Embryol; 2005; 46(2):87-92. PubMed ID: 16286991
[TBL] [Abstract][Full Text] [Related]
18. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in rheumatoid arthritis.
Kim JW; Kong JS; Lee S; Yoo SA; Koh JH; Jin J; Kim WU
Exp Mol Med; 2020 May; 52(5):843-853. PubMed ID: 32461558
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
